earli
drug
suscept
surveil
influenza
virus
europ
reveal
influenza
virus
subtyp
circul
winter
season
resist
neuraminidas
inhibitor
oseltamivir
resist
aris
due
histidin
tyrosin
substitut
neuraminidas
activ
site
nomenclatur
current
method
detect
mutat
involv
endpoint
revers
transcript
polymeras
chain
reaction
follow
nucleotid
sequenc
accur
approach
limit
timeconsum
labourintens
expens
herein
describ
onestep
allel
discrimin
assay
rapidli
h
detect
resist
mutat
sensit
assay
low
copi
per
reaction
capabl
detect
antivir
resist
mutat
mixtur
wild
type
mutant
target
elsevi
bv
right
reserv
influenza
viru
member
genu
orthomyxovirida
rna
virus
import
human
pathogen
caus
signific
annual
global
morbid
mortal
increas
widespread
concern
possibl
emerg
pandem
strain
influenza
lipatov
et
al
inhibitor
first
drug
use
specif
influenza
midseventi
howev
resist
drug
emerg
rapidli
vitro
vivo
resist
strain
appear
fulli
pathogen
transmiss
hayden
hay
oseltamivir
zanamivir
neuraminidas
inhibitor
nai
repres
specif
famili
antivir
drug
licens
prevent
treatment
influenza
b
gubareva
et
al
hayden
et
al
treanor
et
al
consid
class
drug
would
far
less
like
promot
develop
drug
resist
interact
highli
conserv
residu
viral
neuraminidas
burmeist
et
al
taylor
von
itzstein
global
nai
suscept
network
collabor
world
health
organis
creat
monitor
emerg
nairesist
viral
mutant
found
recent
spontan
resist
nai
littl
emerg
resist
treat
patient
zambon
hayden
surveil
previou
year
found
circul
virus
resist
oseltamivir
none
zanamivir
monto
et
al
usual
occur
follow
treatment
shown
readili
transmiss
consid
due
possibl
decreas
viru
fit
colacino
et
al
gubareva
et
al
herloch
et
al
ive
et
al
tai
et
al
yen
et
al
predomin
influenza
virus
circul
europ
season
subtyp
virus
antigen
similar
asolomon
viru
includ
northern
hemispher
vaccin
howev
recent
surveil
studi
shown
signific
proport
circul
virus
present
resist
oseltamivir
euro
surveil
analysi
influenza
virus
european
countri
isol
novemb
june
show
resist
oseltamivir
mean
test
sampl
analys
retain
sensit
altern
nai
zanamivir
residu
proton
pump
blocker
amantadin
protein
euro
surveil
studi
date
also
shown
consider
differ
pattern
resist
differ
geograph
region
evid
influenza
virus
arisen
directli
result
treatment
oseltamivir
current
prescrib
wide
european
countri
global
surveil
coordin
also
subsequ
found
evid
resist
virus
north
america
far
east
clinic
experi
norway
suggest
individu
becom
ill
oseltamivir
resist
strain
influenza
similar
spectrum
ill
infect
wildtyp
season
influenza
euro
surveil
although
sporad
low
level
transmiss
drugresist
virus
may
occur
sinc
nai
class
drug
first
licens
escuret
et
al
gubareva
et
al
gubareva
et
al
ive
et
al
kiso
et
al
mckimmbreschkin
et
al
whitley
et
al
winter
season
first
time
widespread
sustain
transmiss
virus
commun
current
method
monitor
drug
resist
includ
phenotyp
genotyp
analysi
neuraminidas
gene
meijer
et
al
pyrosequenc
bright
et
al
measur
hemagglutin
titer
presenc
drug
bright
et
al
su
et
al
microarray
detect
adamantin
resist
townsend
et
al
flow
cytometr
analysi
virusinfect
cell
mcsharri
et
al
timeconsum
new
molecular
techniqu
requir
urgent
rapid
detect
influenza
oseltamivir
resist
mutat
monitor
transmiss
commun
begin
clinic
investig
diseas
sever
respons
antivir
follow
infect
rapid
assay
h
develop
use
onestep
allel
discrimin
revers
transcript
realtim
polymeras
chain
reaction
ad
rtpcr
detect
oseltamivir
resist
mutat
influenza
gene
respiratori
sampl
sent
nation
viru
refer
laboratori
nvrl
epidemiolog
investig
test
molecular
screen
influenza
realtim
pcr
use
intern
control
multiplex
influenza
b
assay
gunson
et
al
oseltamivir
prescrib
routin
ireland
patient
respiratori
specimen
obtain
treat
season
follow
direct
sequenc
influenza
cdna
six
sampl
preval
found
oseltamivir
resist
mutat
valid
panel
assembl
compris
respiratori
sampl
influenza
season
n
includ
rna
extract
throat
swab
specimen
follow
posit
wildtyp
influenza
five
influenza
posit
mutant
influenza
posit
influenza
b
posit
nine
sampl
neg
influenza
b
specif
ad
rtpcr
assay
test
crossreact
potenti
coinfect
viral
pathogen
includ
respiratori
syncyti
viru
parainfluenza
parainfluenza
human
metapneumoviru
human
coronaviru
human
coronaviru
mump
viru
measl
viru
coxsacki
viru
adenovirusbocaviru
coinfect
two
type
neg
control
includ
ad
rtpcr
assay
run
compris
rna
influenza
b
neg
sampl
templat
control
sampl
list
identifi
previous
pcrbase
type
andor
sequenc
method
rna
valid
panel
extract
respiratori
specimen
use
modifi
version
manufactur
instruct
qiaamp
viral
rna
minikit
qiagen
crawley
uk
l
respiratori
specimen
ad
equal
volum
kit
lysi
buffer
avl
carrier
rna
ad
g
l
heat
c
min
l
ethanol
ad
appli
column
wash
per
manufactur
instruct
final
elut
l
kit
eb
buffer
preheat
c
onestep
allel
discrimin
revers
transcript
realtim
polymeras
chain
reaction
ad
rtpcr
carri
use
l
rna
eluat
l
reaction
volum
superscript
iii
platinum
one
step
qrtpcr
system
invitrogen
appli
biosystem
sd
follow
cycl
paramet
c
min
c
c
min
cycl
data
acquisit
perform
fam
vic
filter
annealingextens
stage
oligonucleotid
primer
final
concentr
appli
biosystem
ad
rtpcr
follow
sens
antisens
final
concentr
allel
specif
probe
dye
minor
groov
bind
nonfluoresc
quencher
mgbnfq
ctcataatgaaaattgmgbnfq
oseltamivir
sensit
probe
cctcataataaaaattgmgbnfq
oseltamivir
resist
probe
five
influenza
mutant
describ
work
submit
influenza
databas
http
wwwflulanlgov
order
determin
limit
detect
ad
rtpcr
assay
cdna
fragment
amplifi
use
primer
sequenc
confirm
influenza
oseltamivir
sensit
sampl
sequenc
confirm
influenza
oseltamivir
resist
sampl
qiagen
onestep
rtpcr
kit
qiagen
crawley
uk
follow
reaction
condit
c
min
c
min
cycl
c
c
c
final
extens
c
min
influenza
gene
amplicon
purifi
use
pcr
purif
kit
qiagen
crawley
uk
quantifi
nanodrop
spectrophotomet
standard
curv
gener
employ
serial
dilut
amplicon
nucleas
free
water
linear
assay
sensit
copi
per
ad
rtpcr
reaction
determin
triplic
employ
ad
rtpcr
target
mutat
confer
oseltamivir
resist
aris
cytosin
thymin
substitut
influenza
gene
nucleotid
posit
influenza
asolomon
vaccin
strain
detect
allel
discrimin
strategi
use
two
differ
label
probe
across
singl
nucleotid
polymorph
snp
sensit
ad
rtpcr
influenza
wildtyp
copi
reaction
detect
wherea
copi
mutant
target
snp
detect
probe
detect
reaction
copi
target
reaction
copi
see
fig
b
assay
linear
rang
copi
slope
correl
coeffici
r
valu
target
demonstr
broad
dynam
detect
rang
method
effici
amplif
analysi
assay
result
show
neg
control
templat
control
influenza
neg
sampl
emit
detect
fluoresc
either
fam
vic
filter
background
level
fluoresc
signal
emit
follow
ad
rtpcr
valid
panel
seen
fig
b
influenza
sequenc
confirm
oseltamivir
sensit
specimen
emit
fluoresc
detect
vic
filter
nm
howev
five
influenza
oseltamivir
resist
mutant
contain
c
snp
emit
fluoresc
fam
probe
bound
nm
concord
observ
sequenc
data
new
ad
rtpcr
assay
valid
panel
run
duplic
mean
ct
valu
replic
rang
wildtyp
oseltamivir
resist
mutant
experi
highest
ct
valu
repeat
replic
sampl
howev
routin
diagnost
use
repeat
extract
andor
sequenc
could
recommend
confirm
result
sampl
high
ct
valu
crossreact
observ
ad
rtpcr
primer
probe
influenza
posit
specimen
common
viral
respiratori
pathogen
ascertain
abil
ad
rtpcr
amplifi
mix
popul
wildtyp
influenza
fig
determin
limit
detect
ad
rtpcr
assay
influenza
b
quantifi
standard
rang
copi
run
triplic
target
plot
ct
cross
threshold
valu
versu
log
copi
number
standard
pcr
paramet
includ
assay
mutant
virus
quantifi
amplicon
mix
follow
copi
number
ratio
target
assay
triplic
data
shown
sampl
contain
mix
popul
copi
found
emit
fluoresc
fam
probe
bound
vic
probe
bound
fig
demonstr
specimen
contain
speci
wildtyp
oseltamivir
sensit
drug
resist
mutat
gene
distinguish
employ
ad
rtpcr
threshold
concentr
detect
wildtyp
mutant
found
least
copi
mutant
mix
popul
copi
wildtyp
fig
consider
concern
polit
medic
scientif
commun
likelihood
futur
influenza
pandem
reason
mani
countri
decid
stockpil
nai
oseltamivir
recommend
countri
develop
strateg
plan
pandem
prepared
crucial
compon
plan
involv
stockpil
oseltamivir
could
use
treat
infect
individu
initi
stage
outbreak
slow
persontoperson
spread
viru
attempt
control
propag
balic
et
al
ferguson
et
al
ferguson
et
al
ferguson
et
al
gani
et
al
germann
et
al
hayden
longini
et
al
longini
et
al
moghada
et
al
monto
monto
moscona
moscona
emerg
influenza
antivir
resist
mutant
across
northern
hemispher
forc
reapprais
transmiss
fit
virus
therefor
improv
rapid
diagnost
method
requir
identifi
rapidli
new
circul
resist
strain
also
rationalis
use
altern
therapeut
option
earli
infect
chutinimitkul
et
al
report
similar
approach
detect
homolog
mutat
highli
pathogen
avian
influenza
howev
littl
sequenc
homolog
exist
avian
human
gene
ad
rtpcr
assay
describ
absolut
specif
human
influenza
genet
drift
viral
rna
genom
lack
proof
read
caus
chang
assay
sensit
time
due
mutat
primer
andor
probe
bind
site
design
degener
oligonucleotid
primer
probe
set
obviat
decreas
assay
sensit
due
genet
drift
target
sequenc
ad
rtpcr
assay
employ
downstream
primari
screen
approach
detect
influenza
posit
failur
snp
assay
may
well
attribut
genet
drift
howev
someth
encount
date
present
assay
allow
comprehens
screen
influenza
virus
without
timeconsum
costli
sequenc
approach
envisag
could
employ
part
influenza
molecular
confirmatori
strategi
conjunct
influenza
subtyp
suggest
second
line
assay
follow
first
influenza
diagnosi
would
invalu
tool
surveil
epidemiolog
purpos
also
diagnost
therapeut
aid
physician
intend
treat
patient
oseltamivir
influenza
mutat
moment
mutat
confer
resist
nai
detect
circul
person
person
appear
therefor
relev
mutat
screen
gener
nontreat
popul
import
point
case
concern
patient
alreadi
undergo
treatment
extens
screen
resist
mutat
would
requir
final
new
molecular
detect
assay
could
also
use
prospect
clinic
studi
ascertain
whether
differenti
long
term
outcom
treatment
respons
patient
infect
either
wildtyp
influenza
virus
harbour
antivir
resist
gene
mutat
